Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced the ...

First-in-class steroid-toxicity outcome assessments licensed by argenx to support development of novel steroid-sparing ...

We recently compiled a list of the 10 Best Immunotherapy Stocks to Buy Now. In this article, we are going to take a look at ...

其中，核心产品 艾加莫德第三季度全球销售收入为 5.73 亿美元，比去年同期（ 3.29 亿美元）增长 74% ； 今年 前三季度收入为 14.49 亿美元，比去年同期（ 8.16 亿美元）增长 77% ，成为自勉领域又一重磅炸弹级别的药物 。

Collaboration to leverage Steritas’ STOX Suite in developing innovative treatments for autoimmune diseases.

文章中强调的Argenx SE强劲的财务表现和前景可观的管线得到了最新InvestingPro数据和提示的进一步支持。截至2024年第二季度,公司过去12个月的收入增长显著,增幅达98.69%,2024年第二季度的季度增长为74.15%。这与文章提到的连续11个季度增长和第三季度令人印象深刻的$573 million净销售额相一致。

周二,Wolfe Research将argenx SE (NASDAQ: ARGX)的股票评级从Peerperform上调至Outperform,目标价为697.00美元。该公司预计,在肌炎和PFS项目的推动下,argenx到2025年将呈现积极发展态势,并有望在重症肌无力(MG)市场保持主导地位,尤其是在竞争对手Biohaven和Immunovant发布最新消息后。 Wolfe Research ...

Atria Investments Inc lessened its holdings in shares of argenx SE (NASDAQ:ARGX – Free Report) by 1.0% in the third quarter, ...

In a report released today, Joon Lee from Truist Financial assigned a Buy rating to Argenx Se (ARGX – Research Report). The company’s shares closed last Friday at $564.23. Don't Miss our Black Friday ...

(医药健闻2024年11月12日讯)再鼎医药和argenx宣布，国家药品监督管理局已批准卫力迦®（艾加莫德皮下注射）的补充生物制品上市许可申请，用于治疗慢性炎性脱髓鞘性多发性神经根神经病（CIDP）成人患者。艾加莫德是国内首个且目前唯一获批CIDP适应证的药物，每周注射一次。这一批准为长期受CIDP困扰的患者提供了新的治疗选择。 再鼎医药与argenx达成独家许可协议，在大中华区开发和商业化艾加莫 ...

Argenx (NASDAQ:ARGX) shares trended higher on Tuesday after Wolfe Research upgraded the Dutch biotech to Outperform from Peer ...